What is the appropriate dosing regimen and contraindications for prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?

Prasugrel Dosing and Contraindications in ACS with PCI

For patients with acute coronary syndrome undergoing PCI, prasugrel should be administered as a 60 mg loading dose followed by 10 mg daily maintenance (5 mg daily if body weight <60 kg or age ≥75 years), but is absolutely contraindicated in patients with prior stroke or TIA. 1, 2

Dosing Regimen

Loading Dose

• 60 mg orally given promptly after coronary anatomy is defined and decision for PCI is made 1, 2
• Administer no later than 1 hour after PCI 3
• Do NOT give before coronary anatomy is known 4, 5—this is a critical safety measure to avoid unnecessary bleeding risk if CABG becomes necessary

Maintenance Dose

Standard dosing:

• 10 mg once daily for patients ≥60 kg and age <75 years 1, 2

Reduced dosing (5 mg daily) required for:

• Body weight <60 kg 1, 2
• Age ≥75 years (use with extreme caution; generally not recommended except in high-risk patients with diabetes or prior MI) 6, 2

Duration

• At least 12 months of dual antiplatelet therapy with aspirin 1, 7
• Continue unless bleeding risk outweighs benefit 1

Absolute Contraindications

Class III (Harm):

1. Prior stroke or transient ischemic attack (TIA) 1, 8, 9, 2

   • This is the most critical contraindication
   • Associated with increased intracranial hemorrhage and net harm 10
   • No exceptions to this contraindication

2. Active pathological bleeding 2

3. Hypersensitivity to prasugrel or any component 2

Relative Contraindications and High-Risk Situations

Exercise extreme caution or avoid in:

• Age ≥75 years: Increased fatal and intracranial bleeding risk 6, 2

  • May consider only in very high-risk situations (diabetes + prior MI) where benefit may outweigh risk 6, 2

• Body weight <60 kg: Increased exposure to active metabolite and bleeding risk 6, 2

  • If used, reduce maintenance dose to 5 mg daily 1, 2

• Patients likely to undergo urgent CABG: Do not start prasugrel 2

  • If already on prasugrel, discontinue at least 7 days before surgery 6, 2
  • CABG-related bleeding risk: 14.1% with prasugrel vs 4.5% with clopidogrel 2

• Propensity to bleed or concomitant medications increasing bleeding risk (warfarin, heparin, NSAIDs, fibrinolytics) 6, 2

Clinical Context and Timing

When prasugrel is preferred over clopidogrel:

• STEMI managed with primary PCI 1
• NSTE-ACS undergoing PCI 1
• Patients NOT at high bleeding risk and WITHOUT stroke/TIA history 10

Critical timing consideration: The most recent 2025 ACC/AHA guidelines emphasize that prasugrel should be given after coronary anatomy is defined 1, distinguishing it from ticagrelor which may be given earlier. This prevents unnecessary exposure in patients who may need CABG.

Comparison with Alternatives

Prasugrel vs Clopidogrel:

• More potent and consistent platelet inhibition 3
• Faster onset of action 3
• Reduced ischemic events but increased bleeding 6, 10

When to choose clopidogrel instead:

• Prior stroke/TIA (absolute indication) 1
• Age ≥75 years without high-risk features 1
• Body weight <60 kg (or use reduced prasugrel dose) 1
• Prasugrel unavailable or contraindicated 1
• Uncertain need for CABG 4

Monitoring and Management

Bleeding risk is highest in first 7 days 2—maintain heightened vigilance during this period.

If bleeding occurs:

• Suspect bleeding in any hypotensive patient post-procedure 2
• Manage bleeding without discontinuing prasugrel if possible 2
• Platelet transfusions may be less effective within 6 hours of loading dose or 4 hours of maintenance dose 2

Premature discontinuation increases risk of:

• Stent thrombosis
• Myocardial infarction
• Death 2

Restart as soon as safely possible if temporarily discontinued 2.